TELESIS BIO INC by Telesis Bio, Inc. Financials - Benzinga

TELESIS BIO INC by Telesis Bio, Inc.

TBIOOTCEM

Trade with Public

Trade with Public

$3.23

가까이에: Oct 7, 5:00 PM EST

개요 뉴스 실적 전망재무심리 지분 현황 비교

TELESIS BIO INC by Telesis Bio, Inc. Financials

TELESIS BIO INC by Telesis Bio, Inc. (TBIO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Dow Surges Over 250 Points; Accenture Earnings Top Views

Avi Kapoor

Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase

Avi Kapoor

PRO
Telesis Bio Q2 Adj $(7.62) Misses $(4.03) Estimate, Sales $1.55M Miss $6.50M Estimate

Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(7.62) per share which missed the analyst consensus estimate of $(4.03) by 89.08 percent. This is a 51.19 percent decrease over losses of $(5.04) per share from the

Benzinga Newsdesk

PRO
Telesis Bio Q1 2024 Adj EPS $(5.52) Misses $(0.23) Estimate, Sales $3.440M Miss $6.900M Estimate

Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(5.52) per share which missed the analyst consensus estimate of $(0.23) by 2300 percent. The company reported quarterly sales of $3.440 million which missed the

Benzinga Newsdesk

PRO
Telesis Bio Q4 EPS $(0.61) Misses $(0.22) Estimate, Sales $6.98M Miss $7.00M Estimate

Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.22) by 177.27 percent. This is a 117.86 percent decrease over losses of $(0.28) per share from

Benzinga Newsdesk

PRO
Telesis Bio Sees Prelim. 2023 Total Consolidated Revenue Of $27.5M, Up From $27.4M YoY; Sees FY24 Total Revenue $7M, Down From $9.5M YoY

Total consolidated revenue for the 2023 fiscal year is expected to be $27.5 million, up slightly from $27.4 million achieved in 2022.Total revenue for the fourth quarter of 2023 is expected to be $7.0 million, a 26.3%

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved